Antibody–drug conjugates come of age in oncology
C Dumontet, JM Reichert, PD Senter… - Nature Reviews Drug …, 2023 - nature.com
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …
EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance
Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …
Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer
Sacituzumab govitecan (SG), the first antibody–drug conjugate (ADC) approved for triple-
negative breast cancer, incorporates the anti-TROP2 antibody hRS7 conjugated to a …
negative breast cancer, incorporates the anti-TROP2 antibody hRS7 conjugated to a …
Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers
J Yu, T Fang, C Yun, X Liu, X Cai - Frontiers in Molecular Biosciences, 2022 - frontiersin.org
Members of the human epidermal growth factor receptor (HER) family, which includes HER1
(also known as EGFR), HER2, HER3 and HER4, have played a central role in regulating cell …
(also known as EGFR), HER2, HER3 and HER4, have played a central role in regulating cell …
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment
modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently …
modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently …
Targeting HER2 heterogeneity in breast cancer
E Hamilton, M Shastry, SM Shiller, R Ren - Cancer Treatment Reviews, 2021 - Elsevier
The identification of Human epidermal growth factor receptor 2 (HER2) as a target in breast
cancer and the subsequent development of HER2-targeted therapies has revolutionized the …
cancer and the subsequent development of HER2-targeted therapies has revolutionized the …
Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
E Rassy, L Rached, B Pistilli - The Breast, 2022 - Elsevier
The identification of the HER2 alteration as an actionable oncogenic driver in breast cancer
has propelled the development of HER-targeting monoclonal antibodies (mAb) such as …
has propelled the development of HER-targeting monoclonal antibodies (mAb) such as …
Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs
Simple Summary A proportion of breast tumors bear the oncogenic transmembrane tyrosine
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …
[HTML][HTML] Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges
Y Yu, Y Yang, H Li, Y Fan - Cancer Treatment Reviews, 2023 - Elsevier
In non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2
(HER2) alterations, chemotherapy remains the standard treatment over a decade, due to the …
(HER2) alterations, chemotherapy remains the standard treatment over a decade, due to the …
Antibody–drug conjugates in breast cancer: current status and future directions
C Mark, JS Lee, X Cui, Y Yuan - International Journal of Molecular …, 2023 - mdpi.com
Antibody drug conjugates (ADCs) are novel medications that combine monoclonal
antibodies with cytotoxic payloads, enabling the selective delivery of potent drugs to cancer …
antibodies with cytotoxic payloads, enabling the selective delivery of potent drugs to cancer …